Lawrence Klein

Insider Reports History

Entity
Individual
Location
C/O Crispr Therapeutics Ag, 610 Main Street 7 Th Floor, Cambridge, MA
Signature
/s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Lawrence Klein:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Oruka Therapeutics, Inc. President and CEO, Director Common Stock 852K $2.54M $2.98 Aug 29, 2024 Direct
Jasper Therapeutics, Inc. Director Stock Option (right to buy) 47K Jun 7, 2023 Direct
CRISPR Therapeutics AG CBO & COO Restricted Stock Units 12.5K Aug 16, 2022 Direct
Dyne Therapeutics, Inc. Director Stock Option (right to buy) 7.22K Jul 5, 2022 Direct

Insider Reports Filed by Lawrence Klein

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ORKA Oruka Therapeutics, Inc. Aug 29, 2024 0 $0 3 Sep 6, 2024 President and CEO, Director
JSPR Jasper Therapeutics, Inc. Jun 7, 2023 1 $0 4 Jun 8, 2023 Director
JSPR Jasper Therapeutics, Inc. Oct 12, 2022 1 $0 4 Oct 13, 2022 Director
CRSP CRISPR Therapeutics AG Aug 16, 2022 1 $0 4 Aug 18, 2022 CBO & COO
DYN Dyne Therapeutics, Inc. Jul 5, 2022 1 $0 4 Jul 6, 2022 Director
DYN Dyne Therapeutics, Inc. Jun 3, 2022 1 $0 4 Jun 6, 2022 Director
JSPR Jasper Therapeutics, Inc. Mar 21, 2022 1 $0 4 Mar 23, 2022 Director
CRSP CRISPR Therapeutics AG Mar 10, 2022 6 -$193K 4 Mar 14, 2022 CBO & COO
CRSP CRISPR Therapeutics AG Feb 18, 2022 2 $0 4 Feb 22, 2022 CBO & COO
CRSP CRISPR Therapeutics AG Dec 3, 2021 3 -$774K 4 Dec 7, 2021 CBO & COO
CRSP CRISPR Therapeutics AG Oct 15, 2021 1 $0 4 Oct 18, 2021 CBO & COO
JSPR Jasper Therapeutics, Inc. Sep 24, 2021 0 $0 3 Oct 1, 2021 Director
CRSP CRISPR Therapeutics AG Sep 10, 2021 3 -$496K 4 Sep 14, 2021 CBO & COO
DYN Dyne Therapeutics, Inc. May 26, 2021 1 $0 4 May 27, 2021 Director